In ACS with planned invasive evaluation, prasugrel vs ticagrelor reduced a composite of death, MI, or stroke at 1 y
Authors: Dominic L. Raco
Journal: Annals of Internal Medicine (2020)

ACP Journal Club21 January 2020In ACS with planned invasive evaluation, prasugrel vs ticagrelor reduced a composite of death, MI, or stroke at 1 yDominic L. Raco, MD, FRCPCDominic L. Raco, MD, FRCPCMcMaster University, Hamilton, Ontario, Canada, William Osler Health System, Brampton, Ontario, Canada (D.L.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202001210-005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationSchüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524-34. https://pubmed.ncbi.nlm.nih.gov/31475799Clinical Impact RatingsGIM/FP/GP: Hospitalists: Cardiology: Critical Care: References1 Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. [PMID: 11519503] Google Scholar2 Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800. [PMID: 25773268] Google Scholar3 Ueda P, Jernberg T, James S, et al. External validation of the DAPT score in a nationwide population. J Am Coll Cardiol. 2018;72:1069-78. [PMID: 30158058] Google Scholar4 Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. [PMID: 19717846] Google Scholar5 Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15. [PMID: 17982182] Google Scholar6 Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213-60. [PMID: 28886622] Google Scholar Author, Article, and Disclosure InformationAffiliations: McMaster University, Hamilton, Ontario, Canada, William Osler Health System, Brampton, Ontario, Canada (D.L.R.)Disclosures: The commentator has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-2922.This article was published at Annals.org on 7 January 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoIn stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding Dominic L. Raco Metrics 21 January 2020Volume 172, Issue 2Page: JC5KeywordsAbsolute risk reductionAcute coronary syndromeAspirinHemorrhageIntent to treat analysisMortalityMyocardial infarctionPercutaneous coronary interventionSt segment elevation myocardial infarctionStroke ePublished: 21 January 2020 Issue Published: 21 January 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...